Article Listing - Gilead’s investigational antiviral elvitegravir meets 48-week primary goal

US RESISTANCE TO DRUG PRICE RISES

13 April 1992

The US pharmaceutical industry will continue to face growing resistance from the federal government and also from private forces towards...

EXPANSION AT SILESIA IN CHILE

13 April 1992

The Chilean pharmaceutical comp-any Silesia is continuing to expand at is base in Santiago. The company its currently working on...

ROCHE'S LAZABEMIDE IN PHASE III NEXT YEAR

13 April 1992

Hoffmann-La Roche has indicated that it expects to begin Phase III trials with its mono-amine oxidase type B-selective inhibitor lazabemide...

DEPRESSION: THE COST TO SOCIETY

6 April 1992

The costs of depression to the National Health Service in the UK are L 333 million per year, according to...

ROBERTS PHARMA ACQUIRES NCRC

6 April 1992

The US concern Roberts Pharma-ceutical has reached a definitive agreement to acquire the National Clinical Research Centers in the USA...

ICN HUBBER GROUP IN SPAIN

6 April 1992

The ICN Hubber Group is investing 1.7 billion pesetas ($2.2 million) in a new pharmaceutical plant near Barcelona in Spain....

US FDA USER FEES: "THE TIME HAS COME"

6 April 1992

People in the US Food and Drug Administration-regulated industries now recognize that the time has arrived for user fees to...

WORLD MARKET FOR BIO-DRUGS

6 April 1992

Biopharmaceuticals will be the single fastest-growing segment of the total pharmaceutical market worldwide in the 1990s, with average annual growth...

TAMOXIFEN OF BENEFIT IN OSTEOPOROSIS?

6 April 1992

A US study looking at the effects of Imperial Chemical Industries' synthetic anti-estrogen Nolvadex (tamoxifen) in post-menopausal women with early-stage...

DRUGS AND SWEDEN'S HEALTH BILL

6 April 1992

Sales of pharmaceutical products in Sweden totaled 10 billion krone ($1.6 billion) in 1990, an increase of 1 billion krone...

Showing 94581-94590 of 95558 articles